To include your compound in the COVID-19 Resource Center, submit it here.

AD-519 neutralizing monoclonal antibody directed against the C4 region of gp120 envelope glycoprotein of HIV: Began an open-label Phase I/IIa trial under an inv

Tanox Biosystems Inc., Houston
Product: AD-519

Read the full 67 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE